microbiology review(s)
TRANSCRIPT
CENTER FOR DRUG EVALUATION AND RESEARCH
APPLICATION NUMBER:
125514Orig1s000
MICROBIOLOGY / VIROLOGY REVIEW(S)
---------------------------------------------------------------------------------------------------------This is a representation of an electronic record that was signedelectronically and this page is the manifestation of the electronicsignature.---------------------------------------------------------------------------------------------------------/s/----------------------------------------------------
REYES CANDAU-CHACON07/28/2014
PATRICIA F HUGHES TROOST07/28/2014
Reference ID: 3600333
STN 125514, Merck Sharp & Dohme Corp
3
Section 3.2.P of the BLA pertaining to product quality microbiology of the drug product manufacturing process was reviewed. The BLA, as amended, is recommended for approval from a product quality microbiology perspective pending proposed labeling changes (see section on LABELING) and with the following post-marketing commitment.
PMC: To conduct a study to assess the endotoxin recovery at various time-points from 3 drug product lots spiked with Control Standard Endotoxin (7.5 EU/mL and 10 EU/mL) in vials using the Kinetic Turbidometric Assay. The study protocol and report with data should be submitted by (date to be provided by applicant).
The drug product manufacturing site, Schering Plough Brinny Co., located at Ballinacurra Road, Innishannon, Cork, Ireland (FEI No. 3002808087) was inspected January 27-Februaury 4, 2014 and covered the profiles . The inspection was classified as NAI.
Reference ID: 3599054
(b) (4)
70 Pages Have Been Withheld In Full As b4 (CCI/TS) Immediately Following This Page
STN 125514, Merck Sharp & Dohme Corp
74
CGMP STATUS:
Please refer to the final TB-EER for the compliance status of the manufacturing and testing
facilities.
CONCLUSION:
I. Section 3.2.P of the BLA pertaining to product quality microbiology of the drug product manufacturing process was reviewed. The BLA, as amended, is recommended for approval from a product quality microbiology perspective pending proposed labeling changes (see section on LABELING) and with the following post-marketing commitment.
PMC: To conduct a study to assess the endotoxin recovery at various time-points from 3 drug product lots spiked with Control Standard Endotoxin (7.5 EU/mL and 10 EU/mL) in vials using the Kinetic Turbidometric Assay. The study protocol and report with data should be submitted by (date to be provided by applicant).
II. CMC product specific information and data should be reviewed by the OBP reviewer.
III. Please refer to the final TB-EER for the compliance status of the manufacturing and testing facilities.
Reference ID: 3599054
STN 125514, Merck Sharp & Dohme Corp
75
SIGNATURES/DISTRIBUTION LIST
Primary BMAB Reviewer: Kalavati Suvarna, Ph.D. Date:
Concurring BMAB Team Leader: Patricia. F. Hughes, Ph.D. Date:
cc:
OND/OHOP/DOP II RPM/Sickafuse, Sharon
OC/OMPQ/BMAB TL/Hughes, Patricia
OND/OHOP/DOP II MO/Chuk, Meredith
OND/OHOP/DOP II CDTL /Theoret, Marc
Reference ID: 3599054
3 Pages Have Been Withheld In Full As b4 (CCI/TS) Immediately Following This Page
---------------------------------------------------------------------------------------------------------This is a representation of an electronic record that was signedelectronically and this page is the manifestation of the electronicsignature.---------------------------------------------------------------------------------------------------------/s/----------------------------------------------------
KALAVATI C SUVARNA07/24/2014
PATRICIA F HUGHES TROOST07/25/2014
Reference ID: 3599054
Determining When Pre-License / Pre-Approval Inspections are Necessary
Inspection Waiver Memorandum
Date: 30 May 2014From: Kalavati Suvarna, Ph.D., CDER/OC/OMPQ/BMAB
Deborah Schmiel, Ph.D., OPS/OBP/DMARashmi Rawat, Ph.D., OPS/OBP/DMA
To: BLA File – STN 125514/0Subject: Recommendation to waive a pre-approval inspection Sponsor: Merck Sharp & Dohme CorpManufacturing Facility: Schering Plough Brinny Co., Ballinacurra Road, Innishannon, Cork,
Ireland (FEI: 3002808087).Product: Proposed name KEYTRUDA (pembrolizumab, MK-3475)Indication: Treatment of unresectable or metastatic melanoma patients who have been
previously treated with ipilimumabThrough: Patricia Hughes, Ph.D., Team Leader, CDER/OC/OMPQ/BMAB
Waiver Recommendation
Based on the compliance history of the firm, the current GMP status, and the fact that Schering Plough Brinny Company has been approved to manufacture multiple CDER products using the same manufacturing process, we recommend that the pre-approval inspection of the ScheringPlough Brinny Company drug product manufacturing facility in Cork, Ireland (FEI: 3002808087) be waived for STN 125514/0.
Clearance Routing
{See appended electronic signature page}
_____________________________________________
Zhihao Peter Qiu, Ph.D.Acting Director, Division of Manufacturing and Product Quality, Office of Compliance, CDER
{See appended electronic signature page}
______________________________________________
Kathleen Clouse, Ph.D.Director, Division of Monoclonal Antibodies, Office of Biotechnology Products, OPS, CDER
Reference ID: 3519760
3 Pages Have Been Withheld In Full As b4 (CCI/TS) Immediately Following This Page
---------------------------------------------------------------------------------------------------------This is a representation of an electronic record that was signedelectronically and this page is the manifestation of the electronicsignature.---------------------------------------------------------------------------------------------------------/s/----------------------------------------------------
KALAVATI C SUVARNA06/05/2014
PATRICIA F HUGHES TROOST06/05/2014
DEBORAH H SCHMIEL06/05/2014
RASHMI RAWAT06/06/2014
KATHLEEN A CLOUSE STREBEL06/06/2014
ZHIHAO PETER QIU06/09/2014
Reference ID: 3519760
PRODUCT QUALITY (Biotechnology)FILING REVIEW FOR ORIGINAL BLA/NDA (OBP & DMPQ)
File Name: 5_Product Quality (Biotechnology) Filing Review (OBP & DMPQ) 022409.doc Page 8
Patricia Hughes, Ph.D. 3/31/2014
Team Leader Date
Reference ID: 3480921
---------------------------------------------------------------------------------------------------------This is a representation of an electronic record that was signedelectronically and this page is the manifestation of the electronicsignature.---------------------------------------------------------------------------------------------------------/s/----------------------------------------------------
KALAVATI C SUVARNA03/31/2014
REYES CANDAU-CHACON03/31/2014
PATRICIA F HUGHES TROOST04/01/2014
Reference ID: 3480921